Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Conbercept for Retinopathy of Prematurity
NCT06717412Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, double-blind trial of conbercept in retinopathy of prematurity (ROP) (2 arms). Primary endpoint: Percentage of participants with absence of active ROP and absence of unfavorable structural outcomes in both eyes at 24 weeks. Started Nov 2024; status: recruiting.
02
Drugs
conbercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT06717412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717412.